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Lieuwe DJ Bos1,2*, Marcus J Schultz1 and Peter J Sterk2Abstract
Background: The acute respiratory distress syndrome (ARDS) is a common, devastating complication of critical
illness that is characterized by pulmonary injury and inflammation. The clinical diagnosis may be improved by
means of objective biological markers. Electronic nose (eNose) technology can rapidly and non–invasively provide
breath prints, which are profiles of volatile metabolites in the exhaled breath. We hypothesized that breath prints
could facilitate accurate diagnosis of ARDS in intubated and ventilated intensive care unit (ICU) patients.
Methods: Prospective single-center cohort study with training and temporal external validation cohort. Breath of
newly intubated and mechanically ventilated ICU-patients was analyzed using an electronic nose within 24 hours
after admission. ARDS was diagnosed and classified by the Berlin clinical consensus definition. The eNose was
trained to recognize ARDS in a training cohort and the diagnostic performance was evaluated in a temporal
external validation cohort.
Results: In the training cohort (40 patients with ARDS versus 66 controls) the diagnostic model for ARDS showed
a moderate discrimination, with an area under the receiver–operator characteristic curve (AUC–ROC) of 0.72
(95%–confidence interval (CI): 0.63-0.82). In the external validation cohort (18 patients with ARDS versus 26 controls) the
AUC–ROC was 0.71 [95%–CI: 0.54 – 0.87]. Restricting discrimination to patients with moderate or severe ARDS versus
controls resulted in an AUC–ROC of 0.80 [95%–CI: 0.70 – 0.90]. The exhaled breath profile from patients with
cardiopulmonary edema and pneumonia was different from that of patients with moderate/severe ARDS.
Conclusions: An electronic nose can rapidly and non–invasively discriminate between patients with and without ARDS
with modest accuracy. Diagnostic accuracy increased when only moderate and severe ARDS patients were considered.
This implicates that breath analysis may allow for rapid, bedside detection of ARDS, especially if our findings are
reproduced using continuous exhaled breath profiling.
Trial registration: NTR2750, registered 11 February 2011.
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The acute respiratory distress syndrome is a common,
devastating complication of critical illness that is charac-
terized by bilateral protein rich pulmonary edema due to
injury and inflammation of the lung. A valid and reliable
diagnosis of ARDS is considered essential for clinical man-
agement and to facilitate enrolment of consistent patient
phenotypes into clinical trials [1]. Presently, a new and* Correspondence: l.d.bos@amc.uva.nl
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unless otherwise stated.improved consensus definition of ARDS is used that is
based on clinical, radiological and physiological criteria
[1]. These criteria are highly suitable for epidemiological
studies but only show a moderate correlation with post–
mortem pathological findings [2]. ARDS can be mistaken
for pneumonia (uni–lateral edema, infection and inflam-
mation) or cardiogenic pulmonary edema (CPE) (low–
protein edema due to hydrostatic pressure), and vice versa
[2,3]. Thus, there is need for objective markers to group
phenotypes more consistently [4].
Use of biological markers could improve the diagnostic
process of ARDS since such markers may change before
the clinical criteria of ARDS are met [5]. It can be argued. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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relevant biochemical information for ARDS diagnosis than
plasma markers [6-9]. Exhaled breath contains hundreds
of volatile organic compounds (VOCs) that are produced
with diverse infectious and inflammatory processes, both
in the lung and elsewhere in the body [10-15]. Previous
studies of biological markers in the breath of critically ill
patients focussed on exhaled breath condensate [16-20].
However, direct analysis of volatile metabolites in the gas
phase is also available now [21,22]. This has many advan-
tages, as samples do not require extensive pre–processing,
analysis is rapid and may be performed continuously using
novel technologies [23].
We hypothesized that VOCs could be used to accurately
diagnose and classify ARDS in intubated and ventilated in-
tensive care unit (ICU) patients. The secondary objectives
were to investigate the influence of ARDS severity and the
underlying causal factor (i.e., pulmonary or non–pulmon-
ary) on diagnostic accuracy. Thirdly, we aimed to investi-
gate the classification of uncomplicated pneumonia and
CPE by exhaled breath analysis. Here we focus on exhaled
breath profiling (so–called ‘breath prints’) using a electronic
Nose (eNose) technology that relies on cross-reactive sen-
sors, meaning that each sensor is responsive to a variety of
VOCs [24,25].
Methods
Design, subjects and settings
This was a prospective single centre cohort study. All pa-
tients admitted to the ICU, with the exception of cardiopul-
monary surgery patients, were screened. The only inclusion
criterion was mechanical ventilation within the first 24 hours
of ICU-admission. Exclusion criteria were (1) previous ICU
admission or mechanical ventilation, (2) logistic problems
or (3) explicit objection to research by the family.
Ethical approval and informed consent
The institutional review board of the Academic Medical
Center, Amsterdam, The Netherlands, decided that the
study did not fulfil all criteria for medical research as
stated in the Dutch ‘law on medical research’ because
of the non-invasiveness and absence of burden of
examining exhaled air (IRB: 10.17.0729). It was judged
that exhaled breath could be analyzed without in-
formed consent of the patient. This trial was registered
at the Dutch Trial Register (NTR2750).
Training and validation cohort
The present study strictly adhered to the 25 required
items of STARD–guidelines on the investigation of diag-
nostic accuracy (Additional file 1: Table S1) [26]. During
three inclusion periods of ~ 3 months, between January
2011 and February 2012, newly admitted ICU–patients
were screened during weekdays. Patients included in thefirst 2 periods were used in the training cohort; patients
included in the last period served as a temporal external
validation cohort [27].
Sample size calculation
Based on a pilot study the estimated sensitivity of ex-
haled breath profiling for discriminating the two ex-
tremes, definite ARDS and definite control patients, was
96.5% [28]. Assuming a prevalence of 50%, an alpha of
0.05 and a 95% confidence interval, the predicted sample
size was 104 for the training cohort [29]. A validation
cohort half the size of the training cohort was included,
according to recommendations on design and analysis of
metabolomics studies [30].
Clinical diagnosis of ARDS
A team of trained clinical research fellows prospectively
scored the presence of ARDS [31], which was later re–
evaluated according to the new Berlin definition that in-
cluded the separation in mild, moderate and severe
ARDS [1]. Importantly, the assessors were always blind
for the eNose signal. All observers were trained on sev-
eral occasions before the start of the study. All assessors
had attended meetings in which clinical case vignettes
were discussed and had at least 6 months of work ex-
perience [32].
Competing diagnoses
The diagnosis of community– or hospital–acquired pneu-
monia consisted of adapted Center for Disease Control–
criteria and a post–hoc likelihood of infection was scored
(none, possible, probable or proven; see Additional file 1:
Table S2) [32,33]. In contrast to ARDS, the diagnosis of
CPE required that the findings (acute onset, bilateral infil-
trates and PaO2/FiO2 ratio < 300) were fully explained by
cardiac dysfunction based on echocardiography [1].
Exhaled breath profiling
Existing methodology [21] was adapted for the specific situ-
ation of breath collection in intubated and ventilated ICU–
patients, as reported previously (Figure 1, upper part) [34].
A co–axial tubing system was connected (Universal F2
breathing circuit, Medical product service GmbH, Braunfis,
Germany) to a mechanical ventilator (Galileo ventilator,
Hamilton, Bonaduz, Switzerland or Servo ventilator,
Maquet, Rastatt, Germany) and a heat–moist exchanger
(HME, Medisize, Hillegom, the Netherlands) was placed at
the end as part of routine practice. A T–piece connector
(T–piece; 22 M/22 F with swivel, Medisize, Hillegom, the
Netherlands) was placed between the HME and the swivel
(Catheter mount, Medisize, Hillegom, the Netherlands).
The swivel was connected to the endotracheal tube
(Ruschelit safety clear plus, Teleflex medical, Athlone,
Ireland). To produce a side–stream flow, the T–piece
Figure 1 Sample collection and data analysis. Exhaled breath was sampled and analyzed using an electronic nose with a side–stream
connection distal from the endotracheal tube. This resulted in a response for the 32 polymer sensors in the nano–composite sensor array. The
eNose was trained using sparse–partial least square (SPLS) logistic regression with 10.000–fold cross–validation. Data from the training cohort was
split into a fraction for model building and model evaluation (10 cases and 10 controls). The algorithm that provided the best internally validated
diagnostic accuracy, evaluated by the area under the receiver operating characteristics curve (ROC–AUC), was selected for blind testing in the
validation cohort and the ROC–AUC with optimal sensitivity and specificity was reported. Differences in the predictive algorithm between
different subgroups (severity of disease, pulmonary and non–pulmonary ARDS) were analyzed using non–parametric tests and the ROC–AUC was
reported. Furthermore, the ROC–AUC for distinguishing CPE and pneumonia from ARDS and moderate/severe ARDS only was calculated. A
sensitivity analysis was performed using logistic regression on comorbidities that are known to influence breath prints, the PaO2/FiO2 ratio,
minute volume ventilation and APACHE II and SAPS II scores.
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PHS3/30G 3×5mm 30 m, Medisize, Vantaa, Finland),
which was locked with a three–way stop–cock before
insertion into the ventilatory circuit. Exhaled breath
was collected (approximately 50 ml/min for 1 minute)
and led to a portable eNose, the Cyranose 320 (Smith
Detections, Pasadena, CA), containing a nano–compos-
ite sensor array with 32 polymer sensors. These sensors
swell as volatile organic compounds diffuse into the
polymer thereby causing a change in the electrical re-
sistance. The relative change in electrical resistance is
saved onto an onboard memory and can later be copied
to an offline database. A baseline measurement was per-
formed for 30 seconds through a VOC–filter type A1
(North Safety, Middelburg, the Netherlands). Thereafter,
exhaled air was collected and analyzed on line for 60 sec-
onds, using two separate Cyranose eNoses. This procedure
was repeated. Data from every initial measurement was
disregarded in the analysis because of deviant raw data, as
recommended by the manufacturer [21]. The index test
and reference test were always performed on the sameday, within 24 hours after admission and were blinded for
each other.
Sensor drift over time
We determined sensor drift over time [35]. Per inclusion
period, this shift was assumed to be linear. Sensor data
was corrected for drift over time, per period, by transform-
ation into standardized residuals by linear regression. This
is similar to multiplicative correction, but without the
usage of a chemical standard [36].
Group allocation
ARDS patients were classified as cases and used to train
and validate a diagnostic algorithm. Control patients did
not fulfil the criteria for ARDS, but could have infiltrates
on chest radiography or oxygenation problems, and had
no or a low likelihood of having pneumonia or CPE (e.g.
a patients with interstitial lung disease could be in the
control group). The trained algorithm was used to pre-
dict the probability of group membership in the patients
with competing diagnoses (pneumonia and CPE).
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Differences between the groups were compared using the
Mann–Whitney U or Kruskal–Wallis test for continuous
variables and chi–square for categorical variables. Data
was summarized using the median and 25–75th percentile
for continuous variables and with count and percentage
for categorical variables. All analyses were performed in R
statistics using the R–studio interface [37]. P–values below
0.05 were considered significant.
The eNose was trained using sparse–partial least square
(SPLS) logistic regression with 10.000–fold cross–valid-
ation. SPLS analysis is a form of regression that can select
predictive variables and limit false discovery in situations
were large number of independent variables are investi-
gated in low numbers of individuals [38]. Data from the
training cohort was split into a fraction for model building
and model evaluation (10 cases and 10 controls). The al-
gorithm that provided the best, robust internally validated
diagnostic accuracy, evaluated by the area under the re-
ceiver operating characteristics curve (ROC-AUC), was se-
lected for blind testing in the validation cohort and the
ROC-AUC with optimal sensitivity and specificity was re-
ported. The process of temporal external validation is re-
quired to assess the actual diagnostic accuracy of the
eNose for ARDS [30]. To check for over–fitting of the al-
gorithm, the previous steps were 1000 times repeated with
permutated group allocation.
Differences in the predictive algorithm between different
subgroups (severity of disease, pulmonary and non–pul-
monary ARDS) were analyzed using non–parametric tests
and the ROC-AUC was reported. Furthermore, the ROC-
AUC for distinguishing CPE and pneumonia from ARDS
and moderate/severe ARDS only was calculated. A sensi-
tivity analysis was performed using logistic regression on
comorbidities that are known to influence breath prints
(chronic pulmonary disease and cancer, see Table 1), the
PaO2/FiO2 ratio, minute volume ventilation and measures
of severity of disease (Acute Physiology and Chronic
Health Evaluation (APACHE) II and Simplified Acute
Physiology Score (SAPS) II).
Results
Subjects
Six hundred twenty–one patients were screened, of whom
274 were not eligible and 120 met exclusion criteria (see
Figure 2). Thus, 207 patients were included. Exhaled breath
profiles were not obtained because of technical problems
in 27 patients, leaving 180 patients for analysis. No adverse
events were reported during or shortly after breath collec-
tion. Fifty–eight (32%) patients fulfilled the definition for
ARDS [1], 35 patients were classified as having mild ARDS,
and 22 and 1 patient as moderate and severe ARDS, re-
spectively. 92 (51%) patients did not fulfil the definition for
ARDS; these patients served as control patients. Competingdiagnoses were pneumonia (11 patients) and CPE (19 pa-
tients). None of the control patients progressed towards
ARDS during the first three days of ICU–admission. Table 1
shows baseline characteristics and respiratory parameters.
Sensor drift
The sensor signal of the eNoses demonstrated drift over
the three periods and within the second period (Additional
file 1: Figure S1A). After transformation into standardized
residuals by linear regression, these trends disappeared
(Additional file 1: Figure S1B).
Training and internal validation
SPLS logistic regression resulted in the selection of 7 sen-
sors (sensors 4, 8, 9, 11, 16, 28 and 30), the regression co-
efficients of which can be found in Additional file 1: Table
S3. The AUC–ROC for ARDS in the model development
cohort was 0.73 (95%–confidence interval (CI): 0.62 –
0.84). Internal validation gave an AUC–ROC for ARDS of
0.71 (CI: 0.47 – 0.95). The diagnostic accuracy for the
complete training cohort can be found in Table 2, together
with the optimal sensitivity and specificity.
Temporal external validation
The eNose provided an ROC-AUC of 0.71 (CI: 0.54-0.87)
in the temporal external validation cohort (Table 2). 27 of
the 1000 random permutation tests resulted in a higher
AUC-ROC, which means that chances of false discovery
are 2.7%. A similar diagnostic accuracy was obtained with
external validation using another eNose of the same
manufacturer (AUC–ROC of 0.73 (CI: 0.58 – 0.90)).
Subgroup analyses
The predicted probability of group membership by the
eNose (result of logistic regression) was significantly differ-
ent between moderate/severe ARDS, and mild ARDS
(0.45 vs. 0.36, P = 0.01). The discrimination between mod-
erate or severe ARDS and controls resulted in an AUC–
ROC of 0.80 (CI: 0.70-0.90) with an optimal sensitivity of
91% and a specificity of 62%.
The predicted probability of group membership was not
different between patients with a pulmonary (pneumonia,
aspiration, etc.) and a non–pulmonary cause (sepsis, pan-
creatitis, etc.) for ARDS (0.41 vs. 0.38, P = 0.82).Competing diagnoses
The eNose signal was different between patients with
pneumonia and patients with CPE from patients with
ARDS, but with borderline significance levels (P = 0.05 and
P = 0.05 vs. ARDS, respectively). Statistical significance and
discrimination increased when patients with CPE and
pneumonia were compared to patients with moderate/se-
vere ARDS (P = 0.003 and P = 0.01; Table 2).
Table 1 Patient and physiological characteristics of included patients
Control (n = 92) ARDS (n = 58) Pneumonia (11) CPE (19) P–value
Age (years) 64 (50–75) 57 (54–78) 56 (49–62) 71 (63–79) 0.106
Male (yes) 51 (55) 30 (52) 8 (89) 11 (73) 0.327
APACHE II 20 (15–26) 23 (19–29) 20 (16–24) 23 (20–28) 0.013
SAPS II 48 (37–60) 55 (43–67) 49 (37–55) 57 (46–63) 0.013
Admission type Medical 56 (62) 41 (72) 7 (64) 16 (89) 0.373
Elective surgery 5 (6) 2 (4) 0 (0) 0 (0)
Emergency surgery 29 (32) 14 (25) 2 (11) 4 (36)
Comorbidities Asthma 1 (1) 0 (0) 0 (0) 1 (5) 0.606
COPD 8 (9) 6 (10) 0 (0) 0 (0) 0.773
Other respiratory 5 (5) 2 (3) 1 (9) 1 (5) 0.290
Malignancy 7 (7) 13 (22) 1 (9) 1 (5) 0.090
DM 10 (11) 10 (17) 0 (0) 3 (16) 0.682
Pmax (cmH2O) 16 (11–20) 21 (15–30) 16 (15–24) 24 (19–29) < 0.001
PEEP (cmH2O) 5 (5–6) 8 (5–10) 5 (5–8.5) 8 (5–10) < 0.001
Tidal volume (ml) 456 (393–545) 426 (380–494) 482 (451–579) 410 (373–506) 0.345
Minute volume (l/min) 8.5 (7.4–9.1) 11.0 (9.1–13.3) 11.3 (9.8–12.6) 9.6 (7.9–12.1) < 0.001
PaCO2 (kPa) 5.1 (4.6–5.7) 5.4 (4.6–5.9) 4.7 (4.1–5.6) 4.8 (4.6–5.6) 0.452
PaO2/FiO2 (mmHg/%) 311 (234–398) 212 (165–257) 304 (241–447) 242 (176–264) < 0.001
Leucocytes 109/ml 12.9 (10.2–18.2) 13.4 (8.7–19.4) 14.1 (13.6–15.1) 18.0 (16.0–18.9) 0.053
CRP mg/ml 65 (21–129) 144 (74–237) 135 (62–177) 66 (18–110) 0.002
ICU Mortality 16 (18) 20 (35) 0 (0) 6 (33) 0.023
Continuous variables are expressed as median (25th to 75th percentile). Categorical variables are expressed as number (percentage). Differences between groups
are tested using Kruskal-Wallis one way analysis of variance or Chi–square test (with Yates’ correction if necessary) and P–values are reported.
APACHE II: Acute Physiology and Chronic Health Evaluation II; ARDS: acute respiratory distress syndrome; CPE: cardiogenic pulmonary edema; PEEP: Positive
end–expiratory pressure; Pmax: maximal inspiratory pressure; SAPS: Simplified Acute Physiology Score.
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The influence of co–variates on the association between
exhaled breath and ARDS was assessed by comparing the
log odds–ratio of the signal derived from the eNose (4.9
(CI: 2.5 - 7.6)) for ARDS in an unadjusted logistic regres-
sion model to the log odds-ratio found in a logistic regres-
sion model adjusted for the co–variate (Table 3).
Discussion
This study with a commercially available eNose suggests
that breath analysis might be used to identify patients with
ARDS if the eNose technology would mature towards this
application with increased diagnostic accuracy and sensor
stability. The diagnostic accuracy was good for moderate/
severe ARDS. These findings were confirmed by temporal
external validation. Notably, the exhaled breath profile
from patients with CPE and pneumonia was well distin-
guished from that of patients with moderate/severe ARDS.
These data support the suggestion that eNose assessment
may qualify as a candidate test for future non-invasive
diagnostic approaches of ARDS.
This is the first study to look at the diagnostic accuracy
of an eNose for the diagnosis of ARDS. Earlier studiesfocussed on biological makers in broncho–alveolar lavage
fluid or exhaled breath condensate [12,20,39-42]. These
sampling methods are time–consuming and sample ana-
lysis is not available in the intensive care unit. A pioneer
paper by Schubert et al. reported on gas–chromatography
and mass–spectrometry of the exhaled breath in ARDS pa-
tients, thereby detecting specific compounds in the breath
[13]. The concentration isoprene was reported to be signifi-
cantly lower in the breath of ARDS patients; however, nei-
ther sensitivity nor specificity was given. The present data
extend those results by providing the diagnostic accuracy of
exhaled breath profiling.
The reported AUC-ROC of 0.71 provides moderate ac-
curacy and is lower than previously found accuracies using
the same type of eNose, when discriminating between
other pulmonary diseases. For example, the externally vali-
dated diagnostic accuracy was 0.95 when discriminating
between asthma and COPD [43]. Several explanations can
be given. First, alterations of exhaled VOC patterns may
not always occur during ARDS or do also occur in ICU
patients without ARDS. Second, the index–test may not
be sufficiently accurate, as may be suggested by sensors
drift, even though we carefully dealt with that. Finally, the
Figure 2 Flow of patient inclusion. ARDS: acute respiratory
distress syndrome; CPE: cardiogenic pulmonary edema; MV:
mechanical ventilation.
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mon in diagnostic research [44].
The gold–standard is an inherent problem in current
diagnostic research of ARDS. Indeed, the new ARDS def-
inition was found to be 89% sensitive but only 63% specific
for diffuse alveolar damage, the histological hallmark of
ARDS [2,45,46]. This discordance was most profound in
patients with mild ARDS. In the present study, we were
not able to obtain the histo–pathological gold standard for
ARDS. In general, lack of a gold–standard attributes to a
lower observed diagnostic accuracy [44]. In our study, weTable 2 Diagnostic accuracy of electronic nose analysis
Cohort Comparison
Training ARDS vs. Control
External validation ARDS vs. Control
In-set: subgroup analysis Moderate/severe ARDS vs. Control
Mild ARDS vs. Control
Moderate/severe ARDS vs. Mild ARD
Pulmonary vs. non-pulmonary ARDS
In-set: competing diagnoses CPE vs. ARDS
Pneumonia vs. ARDS
CPE vs. Moderate/severe ARDS
Pneumonia vs. Moderate/severe ARDfound an increasing likelihood for correct classification
with increasing severity of ARDS. Furthermore, there was
no difference in discrimination between patients with a
pulmonary and a non–pulmonary causal factor for ARDS.
These findings are in line with the hypothesis of an imper-
fect reference standard and indirectly support the validity
of exhaled breath analysis for the diagnosis of ARDS.
Patients with ARDS were discriminated from patients
pneumonia and CPE with modest accuracy. However, dif-
ferentiation between these disease states is regarded as
one of the major clinical challenges in this patient popula-
tion and in this scenario the eNose does not seem to pro-
vide answers. Diagnostic accuracy did increase when only
patients with moderate/severe ARDS were regarded as
cases, but was still moderate. Interestingly, the discrimin-
ation between moderate/severe ARDS and controls was
profoundly sensitive whilst comparison to pneumonia was
mostly specific. Thus ARDS can be excluded with confi-
dence when compared to control subjects while it can’t be
when compared to pneumonia patients. Possibly, some
patients in the pneumonia group actually had ARDS but
chest x-ray was too insensitive to detect the bilateral infil-
trates. Alternatively, some patients with ARDS also had
pneumonia and the differences in exhaled VOCs was just
too small to separate these phenotypes adequately.
One of the strengths of this paper is the assessment of
the external validity of the diagnostic algorithm. External
validation is strongly recommended to limit false–discov-
ery and over–fitting of diagnostic models [30]. Other
strong points of this study may be represented by the re-
cruitment of a relatively large number of patients, com-
pletely independent assessment of both index (exhaled
breath analysis) and reference–test (ARDS diagnosis) and
pre–defined subgroup analyses. Although the use of two
ARDS definitions may seem a possible limitation we feel
that we handled this carefully as all analyses were per-
formed with the Berlin definition, which is more clearly
defined with regards to disease severity and radiological
criteria.ROC-AUC Specificity Sensitivity
0.72 (0.63-0.82) 42% 95%
0.71 (0.54-0.87) 50% 89%
0.80 (0.70-0.90) 62% 91%
0.67 (0.56-0.77) 44% 89%
S 0.69 (0.55-0.83) 46% 91%
0.52 (0.37-0.67) 74% 40%
0.65 (0.51-0.79) 58% 74%
0.69 (0.49-0.88) 83% 64%
0.76 (0.61-0.92) 74% 74%
S 0.76 (0.57-0.95) 91% 64%
Table 3 Sensitivity analysis for potential confounders
Model Log odds-ratio P-value for eNose signal
eNose unadjusted 4.9 (2.5-7.6) 0.0001
eNose + comorbidities 4.9 0.0001
eNose + PaO2/FiO2 3.6 0.0089
eNose +minute volume 4.9 0.0002
eNose + APACHE II 5.8 0.0002
eNose + SAPSII 5.7 0.0002
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altered in ARDS were not identified. This would require
the use of gas–chromatography and mass–spectrometry
(GC–MS), currently the best method for VOC–detec-
tion [47]. This is certainly required for understanding of
the underlying pathophysiological pathways leading to al-
tered VOC concentrations in the exhaled breath. VOC–
identification was beyond the objective of the present study,
because we aimed to establish diagnostic accuracy in the
clinical setting. To that end, we performed sensitivity
and specificity analysis based on composite VOC–sig-
nals, thereby taking maximal benefit of the multiple (as
yet unknown) biomarkers involved. Therefore, eNose
technology is adequate for testing hypotheses on diag-
nostic accuracy [25]. Diagnosis by eNose is rapid, cheap
and easy to perform and therefore closer to clinical ap-
plicability than most other methods for exhaled breath
analysis available at this moment.
Second, we cannot exclude that patient–related factors
such as ventilation strategies, therapy, comorbidities and
exposure to metabolic active compounds are (partly) re-
sponsible for the altered exhaled breath signal. However,
sensitivity analyses showed that ventilator settings such as
minute volume ventilation and comorbidity are probably
not responsible for the found signal. It is difficult, if not
impossible, to control for all confounders in an observa-
tional study but this can be accomplished in pre–clinical
experiments. Importantly, lipopolysacharide–induced lung
injury was found to induce changes in exhaled breath pro-
files in three separate experimental rat models [11,48]. It
may very well be that a similar signal was detected in the
present study, using a different analytical technique.
The prevalence of ARDS was high in the studied patient
cohort, and higher than in most previous cohort studies.
Several factors could serve as an explanation for this dis-
crepancy. First, included patients were severely ill, as sug-
gested by the high disease severity scores and the high
mortality. Second, different from other cohorts of critically
ill patients, we excluded patients after cardiopulmonary sur-
gery. Finally, ARDS was assessed prospectively by a team of
trained research fellows. Prospective assessment may iden-
tify patients that could have been missed retrospectively.
In this study, we used SPLS logistic regression analysis
for model development. This algorithm can be used forvariable selection in high dimensional datasets with low
numbers of patients, while maintaining external validity
and limiting false discovery [38]. Another advantage of
SPLS is that the produced model is relatively simple to in-
terpret. Some sensors were found to be predictive of
ARDS when the sensor result was lower compared to con-
trol, as indicated by a negative coefficient in the model
(Table 2). This is probably due to lower breath concentra-
tions of VOCs with affinity to these sensors. Following
GC–MS driven research, we can hypothesize that isoprene
can be one of these VOCs [13]. Interestingly, not all coeffi-
cients were negative: apparently three sensors are affinitive
for VOCs that increase in concentration. Combined, these
findings provide evidence that ARDS is associated with
both up–regulation and down–regulation of volatile
metabolites.
This paper describes exhaled breath analysis as a diag-
nostic tool for ARDS. However, several steps need to be
taken before exhaled breath analysis can be implemented
into clinical practice. Primarily, we need a list of potential
ARDS–biomarkers in exhaled air obtained from controlled
pre–clinical models, thereby excluding confounders as
medication, comorbidities and ventilatory strategies. Sec-
ond, the accuracy of sensors needs to be increased as the
tested commercially available technology proved insuffi-
cient: sensor sensitivity and specificity for VOCs can be
modified targeting potential biomarkers. Drift should be
minimized and sensor-arrays should provide interchange-
able results to allow for application in large clinical trials.
Continuous exhaled breath analysis would allow for moni-
toring. Finally, the lack of a gold standard cannot be solved
easily. In the long run, a move from the diagnostic accur-
acy paradigm towards a test validation paradigm might be
justified [44]. This would allow for the comparison of
added value of several index–tests, including exhaled
breath analysis, in clinical decision–making.
Conclusions
We found that an electronic nose can rapidly and non–in-
vasively discriminate between patients with and without
ARDS with modest accuracy. The diagnostic model was
both externally validated and reproducible. Diagnostic ac-
curacy increased when only moderate and severe ARDS
patients were considered. The exhaled breath profile from
patients with CPE and pneumonia was different from that
of patients with moderate/severe ARDS.
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